COVID Infusion Therapy Effective At Reducing Severity Of Disease — If You Get It Soon Enough

 ========= Old Image Removed =========1Array
(
    [_wp_attached_file] => Array
        (
            [0] => 2021/09/monoclonal-antibody-therapy-e1631215771330.jpg
        )

    [_wp_attachment_metadata] => Array
        (
            [0] => a:5:{s:5:"width";i:1200;s:6:"height";i:675;s:4:"file";s:54:"2021/09/monoclonal-antibody-therapy-e1631215771330.jpg";s:5:"sizes";a:10:{s:6:"medium";a:4:{s:4:"file";s:54:"monoclonal-antibody-therapy-e1631215771330-336x189.jpg";s:5:"width";i:336;s:6:"height";i:189;s:9:"mime-type";s:10:"image/jpeg";}s:5:"large";a:4:{s:4:"file";s:54:"monoclonal-antibody-therapy-e1631215771330-771x434.jpg";s:5:"width";i:771;s:6:"height";i:434;s:9:"mime-type";s:10:"image/jpeg";}s:9:"thumbnail";a:4:{s:4:"file";s:54:"monoclonal-antibody-therapy-e1631215771330-140x140.jpg";s:5:"width";i:140;s:6:"height";i:140;s:9:"mime-type";s:10:"image/jpeg";}s:12:"medium_large";a:4:{s:4:"file";s:54:"monoclonal-antibody-therapy-e1631215771330-768x432.jpg";s:5:"width";i:768;s:6:"height";i:432;s:9:"mime-type";s:10:"image/jpeg";}s:9:"wbhm-icon";a:4:{s:4:"file";s:52:"monoclonal-antibody-therapy-e1631215771330-80x80.jpg";s:5:"width";i:80;s:6:"height";i:80;s:9:"mime-type";s:10:"image/jpeg";}s:13:"wbhm-featured";a:4:{s:4:"file";s:54:"monoclonal-antibody-therapy-e1631215771330-800x450.jpg";s:5:"width";i:800;s:6:"height";i:450;s:9:"mime-type";s:10:"image/jpeg";}s:20:"wbhm-featured-square";a:4:{s:4:"file";s:54:"monoclonal-antibody-therapy-e1631215771330-600x600.jpg";s:5:"width";i:600;s:6:"height";i:600;s:9:"mime-type";s:10:"image/jpeg";}s:18:"wbhm-featured-home";a:4:{s:4:"file";s:54:"monoclonal-antibody-therapy-e1631215771330-553x311.jpg";s:5:"width";i:553;s:6:"height";i:311;s:9:"mime-type";s:10:"image/jpeg";}s:22:"wbhm-featured-carousel";a:4:{s:4:"file";s:54:"monoclonal-antibody-therapy-e1631215771330-470x265.jpg";s:5:"width";i:470;s:6:"height";i:265;s:9:"mime-type";s:10:"image/jpeg";}s:14:"post-thumbnail";a:4:{s:4:"file";s:54:"monoclonal-antibody-therapy-e1631215771330-125x125.jpg";s:5:"width";i:125;s:6:"height";i:125;s:9:"mime-type";s:10:"image/jpeg";}}s:10:"image_meta";a:12:{s:8:"aperture";s:1:"0";s:6:"credit";s:9:"U.S. Navy";s:6:"camera";s:0:"";s:7:"caption";s:0:"";s:17:"created_timestamp";s:1:"0";s:9:"copyright";s:13:"Public Domain";s:12:"focal_length";s:1:"0";s:3:"iso";s:1:"0";s:13:"shutter_speed";s:1:"0";s:5:"title";s:0:"";s:11:"orientation";s:1:"1";s:8:"keywords";a:0:{}}}
        )

    [_wp_attachment_image_alt] => Array
        (
            [0] => Lt. Cmdr. Raben Talvo, left, department head of the Naval Medical Center San Diego Office of Clinical Quality, and Hospital Corpsman 1st Class Angela Ramirez administer monoclonal antibody treatment to a COVID-19-positive patient.
        )

    [_media_credit] => Array
        (
            [0] => Mass Communication Specialist 3rd Class Harley K. Sarmiento
        )

    [_navis_media_credit_org] => Array
        (
            [0] => U.S. Navy
        )

    [_navis_media_can_distribute] => Array
        (
            [0] => 1
        )

    [_wp_attachment_backup_sizes] => Array
        (
            [0] => a:11:{s:9:"full-orig";a:3:{s:5:"width";i:1200;s:6:"height";i:857;s:4:"file";s:31:"monoclonal-antibody-therapy.jpg";}s:14:"thumbnail-orig";a:4:{s:4:"file";s:39:"monoclonal-antibody-therapy-140x140.jpg";s:5:"width";i:140;s:6:"height";i:140;s:9:"mime-type";s:10:"image/jpeg";}s:11:"medium-orig";a:4:{s:4:"file";s:39:"monoclonal-antibody-therapy-336x240.jpg";s:5:"width";i:336;s:6:"height";i:240;s:9:"mime-type";s:10:"image/jpeg";}s:17:"medium_large-orig";a:4:{s:4:"file";s:39:"monoclonal-antibody-therapy-768x548.jpg";s:5:"width";i:768;s:6:"height";i:548;s:9:"mime-type";s:10:"image/jpeg";}s:10:"large-orig";a:4:{s:4:"file";s:39:"monoclonal-antibody-therapy-771x551.jpg";s:5:"width";i:771;s:6:"height";i:551;s:9:"mime-type";s:10:"image/jpeg";}s:14:"wbhm-icon-orig";a:4:{s:4:"file";s:37:"monoclonal-antibody-therapy-80x80.jpg";s:5:"width";i:80;s:6:"height";i:80;s:9:"mime-type";s:10:"image/jpeg";}s:18:"wbhm-featured-orig";a:4:{s:4:"file";s:39:"monoclonal-antibody-therapy-800x450.jpg";s:5:"width";i:800;s:6:"height";i:450;s:9:"mime-type";s:10:"image/jpeg";}s:25:"wbhm-featured-square-orig";a:4:{s:4:"file";s:39:"monoclonal-antibody-therapy-600x600.jpg";s:5:"width";i:600;s:6:"height";i:600;s:9:"mime-type";s:10:"image/jpeg";}s:23:"wbhm-featured-home-orig";a:4:{s:4:"file";s:39:"monoclonal-antibody-therapy-435x311.jpg";s:5:"width";i:435;s:6:"height";i:311;s:9:"mime-type";s:10:"image/jpeg";}s:27:"wbhm-featured-carousel-orig";a:4:{s:4:"file";s:39:"monoclonal-antibody-therapy-371x265.jpg";s:5:"width";i:371;s:6:"height";i:265;s:9:"mime-type";s:10:"image/jpeg";}s:19:"post-thumbnail-orig";a:4:{s:4:"file";s:39:"monoclonal-antibody-therapy-125x125.jpg";s:5:"width";i:125;s:6:"height";i:125;s:9:"mime-type";s:10:"image/jpeg";}}
        )

)
1637646446 
1631111379
Lt. Cmdr. Raben Talvo, left, department head of the Naval Medical Center San Diego Office of Clinical Quality, and Hospital Corpsman 1st Class Angela Ramirez administer monoclonal antibody treatment to a COVID-19-positive patient.

Lt. Cmdr. Raben Talvo, left, department head of the Naval Medical Center San Diego Office of Clinical Quality, and Hospital Corpsman 1st Class Angela Ramirez administer monoclonal antibody treatment to a COVID-19-positive patient.

Mass Communication Specialist 3rd Class Harley K. Sarmiento, U.S. Navy

Monoclonal antibody therapy to lessen the severity of COVID’s delta strain may be the only drug at this time on which vaxxers and anti-vaxxers can agree.

Some anti-vaccination advocates are counting on being able to get the therapy if they contract COVID, while people who are vaccinated but still get the virus turn to it to lessen the effects of the disease.

Antibodies are proteins made by the immune system to clear infections. For viruses such as COVID-19, these proteins are critical to stopping the infection.

But the bottom line is that the therapy does not work unless it is given in the first 10 days of COVID symptoms. Symptoms include fever, chills, loss of taste or smell and muscle aches. A complete list can be found on the CDC website.

“The problem is that our immune system takes two to three weeks to make good antibodies,” said UAB professor Dr. Turner Overton.

Monoclonal antibodies are supplemental manmade antibodies that can be administered early in the course of the infection. The antibodies rapidly bind and kill the COVID virus and reduce the risk of hospitalization by 70% in high-risk unvaccinated people.

“It is incredibly effective if given early enough,” Overton added.

Find infusion locations from the state health department or the National Infusion Center Association

The therapy becomes more important in states such as Alabama, where 2.3 million, or half the state population, have received at least one COVID vaccine. More than one-third of the state’s population, about 1.8 million people, are fully vaccinated, according to the Alabama Department of Public Health.

“There are clinics and hospitals across the state that are offering these lifesaving therapies,” Overton said.

Someone who tests positive for the virus should contact their doctor for a referral for treatment with the antibodies.

Dr. Sarah Nafziger said last week that UAB has multiple infusion clinics, and monoclonal antibody therapy is given in the hospital emergency department when needed. She is a professor of medicine and vice president for UAB Hospital’s Clinical Operations.

“But they are still reserving the treatment for those who need it the most,” Nafziger said. “Not everybody needs it who has COVID. It is really reserved for those who are the highest risk of being hospitalized.”

Women who are pregnant and positive for COVID should consider the therapy infusions, said Dr. Jodie Dionne, assistant professor in the UAB Division of Infectious Diseases and the Associate Director of Global Health in the Center for Women’s Reproductive Health.

She said studies show the antibodies are very effective in keeping people out of the hospital when they have other comorbidities, that is the simultaneous presence of two or more diseases or medical conditions.

“Pregnancy is listed as one of those comorbidities,” Dionne added.

She said UAB is trying to ramp up access for people, including pregnant women, to get the therapies.

Those eligible for the infusions include children aged 12 or older who weigh at least 88 pounds and have a body mass of 25 or higher, according to the U.S. Department of Health and Human Services.

All three doctors agree that the first step to stopping the spread of COVID is to get vaccinated.

The monoclonal antibody treatments include two made by Eli Lilly and a therapeutic cocktail made by Regeneron.

The National Infusion Center Association has a listing of infusion centers for Alabama by place name or ZIP code that can be found here. But the site warns that availability of the treatment at any given place has not been verified recently. Call first.

The ADHP has a state map on its COVID-19 Dashboard Hub showing statewide locations of places offering the infusions. Click on the Monoclonal Antibody Therapy Locations tab.

The map gives the sites of hospitals, medical offices and pharmacies giving the infusions.

Antibody therapies are restricted to high-risk patients and require a drug order, similar to a prescription, from a health care provider.

Health care providers must verify their patient’s eligibility and verify the availability of doses at an authorized infusion site before they refer a patient to schedule treatment.

The centers are busy. For example, in Birmingham, MainStreet Family Care offers the treatments at all of its locations. MainStreet Chief Marketing Officer Betsy Stewart said the number of infusions jumped from 15 a day in July to 60 in August.

Overton said the infusion takes about 20 minutes, then patients are monitored for two hours after the treatment is complete.

He said the infusions are a safe therapy but added, “Please get vaccinated. If we could get all Alabamians vaccinated, we could get our lives back to normal.”

 

Trump picks Oregon Congresswoman Lori Chavez-DeRemer to lead Labor Department

President-elect Donald Trump has nominated Congresswoman Lori Chavez-DeRemer of Oregon to lead the Labor Department. She was one of a few Republicans who support the pro-union PRO Act.

Trump nominates Wall Street investor Scott Bessent as treasury secretary

President-elect Trump nominated Bessent, a former protégé of George Soros to be his next treasury secretary.

In the Marble Bowl, the heated rivalry between Alabama and Auburn is getting ‘wilder’

The Marble Bowl is a competition that pits fans of the University of Alabama against Auburn University. No tight ends or cornerbacks, quarterbacks or linebackers are needed, although they can play, too.

From the Seattle food scene to Barney the purple dinosaur, check out these new podcasts

Looking for conversation starters for the Thanksgiving dinner table? The NPR One team has it covered with podcast recommendations from across public media.

What’s Making Us Happy: A guide to your weekend scrolling, listening and gaming

Each week, guests and hosts on NPR's Pop Culture Happy Hour share what's bringing them joy. This week: TikTok Pride and Prejudice, K-pop star G-Dragon, a Disney cover album, and Astro Bot on the PS5.

For the first time ever, Taliban reps were invited to the big U.N. climate conference

Since the Taliban took power 2021, Afghanistan has not been invited to big climate conferences. And money for projects addressing climate-related issues has been frozen. Are things about to change?

More BirminghamWatch Coverage